ProMIS Neurosciences Appoints Renowned Neuroscientists, Dr. Guy Rouleau and Dr. Alain Dagher to its Scientific Advisory Board

ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting misfolded proteins such as toxic oligomers implicated in the development of neurodegenerative diseases, announced today that it has appointed Drs. Guy Rouleau and Alain Dagher to its scientific advisory board (SAB).

 

Dr. Guy Rouleau, MD, PhD, is Director of The Neuro (Montreal Neurological Institute-Hospital), Chair of the Department of Neurology and Neurosurgery of McGill University, Director of the Department of Neuroscience of McGill University Health Centre, and co-founder of the Tanenbaum Open Science Institute. Over the last two decades, Dr. Rouleau and his team have focused on identifying genes associated with neurological and psychiatric diseases, including autism, amyotrophic lateral sclerosis, hereditary neuropathies, epilepsy and schizophrenia, as well as providing a better understanding of the molecular mechanisms that lead to disease symptoms.

 

Dr. Alain Dagher, MD, has been an attending neurologist at the Montreal Neurological Institute since 1997. His clinical specialty is movement disorders, with a focus on Parkinsonโ€™s Disease. His main research interest is functional brain imaging to understand the function of the basal ganglia, frontal lobes and dopamine in reward-seeking behaviors. This research has shed light on the cognitive deficits in Parkinsonโ€™s disease, stress and anxiety, schizophrenia, drug addiction, obesity, and pathological gambling and other behavioral addictions.

 

โ€œOn behalf of the ProMIS executive team I am delighted to welcome Drs. Rouleau and Dagher to our scientific advisory boardโ€, stated Dr. Neil Cashman, ProMIS Chief Scientific Officer. โ€œTheir outstanding scientific contributions to a broad area of neurodegenerative, neurological and neuropsychiatric diseases is an excellent fit with ProMISโ€™s technology platform and portfolio of antibodies selectively targeting the toxic, misfolded proteins that are implicated in these devastating disorders.โ€

  

ProMIS Neurosciences, Inc. is a development stage biotechnology company focused on discovering and developing antibody therapeutics selectively targeting toxic misfolded oligomers implicated in the development and progression of neurodegenerative diseases, in particular Alzheimerโ€™s disease (AD), amyotrophic lateral sclerosis (ALS) and Parkinsonโ€™s disease (PD). The Companyโ€™s proprietary target discovery engine is based on the use of two complementary computational modeling techniques. The Company applies its molecular dynamics, computational discovery platform -ProMISโ„ข and Collective Coordinates – to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. ProMIS is headquartered in Toronto, Ontario, with offices in Cambridge, Massachusetts. ProMIS is listed on the Toronto Stock Exchange under the symbol PMN, and on the OTCQB Venture Market under the symbol ARFXF

 

www.promisneurosciences.com

 

Twitter and LinkedIn

 

Hot this week

World Class eye care services now accessible in underserved communities with insurance plans

Dr. Ken Moadel, New Yorkโ€™s most trusted name in...

Fintech Visionaries Brett King & Chris Skinner Unite at WebAccountPlus AI Innovation Ltd

WebAccountPlus AI Innovation Ltd., the groundbreaking Swiss fintech firm...

EUROPEโ€™S PUBLISHERS WELCOME EUROPEAN COMMISSION ACTION AGAINST APPLE APP STORE FOR BREACH OF DIGITAL MARKETS ACT

The European Publishers Council (EPC) welcomes the European Commissionโ€™s...

A Place to Heal: Virtue Recovery Center Stands with Veterans and Families Across the United States

Virtue Recovery Center in Las Vegas, NV, is stepping...

A Place to Heal: Virtue Recovery Center Stands with Veterans and Families Across the United States

Virtue Recovery Center in Las Vegas, NV, is stepping...

Topics

Fintech Visionaries Brett King & Chris Skinner Unite at WebAccountPlus AI Innovation Ltd

WebAccountPlus AI Innovation Ltd., the groundbreaking Swiss fintech firm...

EUROPEโ€™S PUBLISHERS WELCOME EUROPEAN COMMISSION ACTION AGAINST APPLE APP STORE FOR BREACH OF DIGITAL MARKETS ACT

The European Publishers Council (EPC) welcomes the European Commissionโ€™s...

CARDIEUX Shocks Shoppers with a Never-Before-Seen 95% Off Luxury Jewelry Code

What started as a rumor is now confirmedโ€”CARDIEUXโ€™s 95%...

Fexco Launches Cross-Industry Payment Orchestration Platform Building on Cruise Market Dominance

Fexco, the Irish-based financial services and fintech company, has...

Related Articles

Popular Categories

spot_imgspot_img